The objectives of this Technology Assessment Report (TAR) were:
•To update a previous TAR on the effectiveness and cost-effectiveness of infliximab in adults with moderate-to-severe CD or fistulising CD who are refractory to or intolerant of conventional treatment.
•To review the evidence on the clinical effectiveness and cost-effectiveness of infliximab in children with moderate-to-severe CD who are refractory to or intolerant of conventional treatment.
•To review the evidence on the clinical effectiveness and cost-effectiveness of a further anti-TNF-α antibody, adalimumab, in adults with moderate-to-severe CD who are refractory to or intolerant of conventional treatment.
•To investigate whether there is evidence for greater clinical effectiveness or cost-effectiveness for either adalimumab or infliximab.